Arch Biopartners Inc
Research Arch Biopartners Inc (ARCH) on Bullrun: market cap CAD 57.06M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARCH
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 57.06M
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 521.01K
- Free cash flow-CAD 108.12K
Valuation Snapshot
latest market cap is CAD 57.06M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 2.70M | -CAD 1.57M | n/a | n/a | CAD 4.16K | CAD 2.53M | -CAD 3.60M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | CAD 57.06M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Arch Biopartners Inc's market cap?
Arch Biopartners Inc's market capitalization is CAD 57.06M.
What does Arch Biopartners Inc do?
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.